Get out your finnies!
An update from Fidia Farmaceutici
Further to previous communications, regarding the development of a hair loss remedy initiated a few months ago, we announce that the study is still in progress, thereby an accurate time frame in which such remedy would be available cannot be defined yet.
Being a pharmaceutical manufacturing company imposes the need for a set of quality, safety and efficacy standards in all R&D and production activities.
Everything we do at Fidia Farmaceutici is focused on improving the quality of life of patients and with the same accuracy and dedication, we are addressing this unmet medical need, a condition that can occur at any age and affects men and women equally, in Italy and worldwide, as corroborated by hundreds of emails and phone calls received during 2016.
Alopecia areata (hair loss) is not a life-threatening disease, nevertheless it can cause serious distress in people. Fidia has made a strong commitment to research and development, to offer all patients who are affected by the problem, a real treatment option – effective, safe and stable – at the end of the entire study.
For this reason, neither exact launch plans nor time-to-market priorities have been defined for the product yet, although we envisage the development of the potential product candidate being completed by 2018.
An update from Fidia Farmaceutici
Further to previous communications, regarding the development of a hair loss remedy initiated a few months ago, we announce that the study is still in progress, thereby an accurate time frame in which such remedy would be available cannot be defined yet.
Being a pharmaceutical manufacturing company imposes the need for a set of quality, safety and efficacy standards in all R&D and production activities.
Everything we do at Fidia Farmaceutici is focused on improving the quality of life of patients and with the same accuracy and dedication, we are addressing this unmet medical need, a condition that can occur at any age and affects men and women equally, in Italy and worldwide, as corroborated by hundreds of emails and phone calls received during 2016.
Alopecia areata (hair loss) is not a life-threatening disease, nevertheless it can cause serious distress in people. Fidia has made a strong commitment to research and development, to offer all patients who are affected by the problem, a real treatment option – effective, safe and stable – at the end of the entire study.
For this reason, neither exact launch plans nor time-to-market priorities have been defined for the product yet, although we envisage the development of the potential product candidate being completed by 2018.
Last edited:
